Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of lgd-4033 liquid in China. Welcome to wholesale bulk high quality lgd-4033 liquid for sale here from our factory. Good service and reasonable price are available.
LGD-4033 Liquid is the liquid oral formulation of Ligandrol (LGD-4033), usually dissolved in solvents such as PEG-400, ethanol, or glycerin to enhance absorption rate. As a selective androgen receptor modulator (SARM), it mainly targets muscle and bone tissues, promoting protein synthesis and muscle growth, while reducing the side effects of traditional anabolic steroids (such as hepatotoxicity or androgenic effects).
Its advantage lies in the flexibility of dose adjustment, which is usually precisely measured using droppers or metering pumps. The common concentration is 5-10 mg/mL. Users usually take 5-20 mg daily within an 8-12 week cycle, and may observe improvements in muscle mass, strength, and recovery ability. However, it may cause mild testosterone suppression, fatigue, or headaches, and the long-term safety is not yet clear.
Due to not being approved by the FDA, this product is only sold as a research chemical and is prohibited for use by sports organizations (such as WADA). When purchasing, attention should be paid to purity and solvent safety to avoid counterfeit or contamination risks.
|
|
|
Ligandrol (LGD-4033) Powder COA
Stability Analysis
Chemical Stability
LGD-4033 Liquid is a non-steroidal selective androgen receptor modulator (SARM), with stable chemical properties. However, the following conditions should be noted:
Storage environment: It needs to be stored at -20℃ in a refrigerated condition and placed in an inert gas environment to prevent moisture absorption (hygroscopicity).
Solubility: It is slightly soluble in chloroform (under heating conditions), methanol, and has a low solubility in acetone. The liquid formulation may be improved in solubility and stability by adjusting the solvent (such as polyethylene glycol or ethanol), but solvents that react with the compound should be avoided.
Light exposure and oxidation: Long-term exposure to light or oxygen may lead to degradation. It is recommended to use a light-proof bottle and be protected with nitrogen gas.
Preparation stability challenge
Risk of liquid dosage form: compared with solid powder, liquid dosage form is more prone to hydrolysis, oxidation or microbial contamination. It is necessary to extend the shelf life by adding stabilizers (such as antioxidants) or adjusting the pH value (the pKa of lgd-4033 is 12.06, and the weak alkaline environment may be more stable).
Half life effect: the elimination half-life of lgd-4033 is 24-36 hours, but the stability of the liquid dosage form needs to be independently evaluated. At present, there is no public data indicating that the liquid dosage form will significantly shorten the validity period of its active ingredient, but it needs to be verified by accelerated stability test (such as 40 ℃/75% RH condition).
User feedback and measured data
Some users reported that under correct storage conditions (light-proof, sealed, and at low temperature), the activity of liquid LGD-4033 could be maintained for 12-18 months, but regular concentration checks were required.
Independent laboratory analysis found that some commercially available liquid products had concentration deviations (±15%) or exceeded the limit of impurities, which may affect stability and safety.
Safety Analysis
Clinical research data
Phase I trial: Healthy males took 1-3 mg daily for 21 days, no serious adverse reactions were reported, but the total testosterone level decreased by 50%, and high-density lipoprotein cholesterol (HDL-C) decreased by 40% (increasing cardiovascular risk).
Phase II trial: In the trial for patients with hip fractures, some subjects experienced mild elevation of transaminases, but did not reach the standard of liver toxicity.
Long-term risks: There are currently no data exceeding 12 weeks of continuous medication, and potential risks include inhibition of the hormone axis, lipid metabolism disorders, and unknown tissue accumulation effects.
Specific risks of the liquid formulation
Dosage accuracy: The liquid formulation requires precise measurement using droppers or measuring cups, and operational errors may lead to dosage fluctuations (±10%), increasing the risk of side effects.
Solvent safety: Some liquid products use propylene glycol or ethanol as solvents, and long-term intake may cause gastrointestinal discomfort or liver burden.
Microbial contamination: Non-sterile formulations may be contaminated by bacteria or fungi due to improper storage, and safety should be ensured through sterility testing.
User actual feedback
Common side effects: Headache (15%), dry mouth (10%), muscle spasms (8%), and mood swings (5%), most of which are mild and reversible.
Serious adverse reactions: A few users reported jaundice (a sign of liver damage) or hypertension, which may be related to excessive dosage (>10 mg/day) or individual susceptibility.
Dependence and withdrawal reactions: Suddenly stopping use after long-term use may lead to weakness or low mood, but there is no evidence of addiction.
Comprehensive Evaluation and Recommendations
Stability summary
The liquid formulation of LGD-4033 can remain stable under low temperature, light-proof, and sealed conditions. However, it is recommended to choose products that have been tested by a third party to ensure concentration and purity. After opening, the liquid should be divided and frozen to avoid repeated freezing and thawing.
Safety rating
Short term use (4-8 weeks): use low dose (≤ 5 mg/day) under professional guidance, with controllable safety, but the blood lipid and liver function need to be monitored.
Long term use: the risk is unknown, and it is not recommended for non-medical purposes.
Contraindications: pregnant women, minors, patients with prostate or breast cancer, and patients with severe cardiovascular diseases.
Usage suggestions
Dose control: For first-time users, start from 2 mg/day and gradually adjust to the target dose.
Cycle management: Use continuously for no more than 8 weeks, then undergo 4 weeks of PCT (such as tamoxifen) to restore hormone levels.
Monitoring indicators: Regularly test testosterone, HDL-C, liver enzymes (ALT/AST), and blood pressure during medication.
Compliance: LGD-4033 is listed as a prohibited substance by the World Anti-Doping Agency (WADA). Athletes should avoid using it.
Absorption and Bioavailability
Absorption Mechanism and Oral Advantages
LGD-4033 Liquid, as a non-steroidal selective androgen receptor modulator (SARM), has a core advantage in its high oral bioavailability (approximately 90%). This characteristic stems from the molecular design of LGD-4033, which avoids the 17α-alkylation structure of traditional steroids (such as testosterone), thereby preventing the metabolic loss caused by the first-pass effect in the liver.
Molecular characteristics: The lipophilicity (logP ≈ 3.5) and moderate molecular weight (338.25 g/mol) of LGD-4033 facilitate its rapid penetration through the intestinal mucosa via passive diffusion. The liquid formulation may be further improved in solubility by optimizing the solvent (such as polyethylene glycol or ethanol), but attention should be paid to the potential irritation of the gastrointestinal tract by the solvent.
Absorption rate: Preclinical studies have shown that LGD-4033 reaches the peak plasma concentration (Cmax) 2-4 hours after oral administration. The liquid formulation may shorten the time to peak concentration to 1-2 hours due to the absence of the disintegration process, but this needs to be verified through human trials.
Food influence: A high-fat diet may delay absorption (Tmax prolonged by 1-2 hours), but it does not affect the overall exposure (AUC). Therefore, it is recommended to take the medication on an empty stomach to reduce individual differences.
Factors influencing bioavailability
Solvent and formulation process
Solvent selection: Liquid formulations commonly use polyethylene glycol 400 (PEG400), ethanol, or dimethyl sulfoxide (DMSO) as solvents. PEG400 can increase solubility and has higher safety, but it may reduce drug permeability; ethanol can enhance membrane permeability, but long-term use may stimulate the gastric mucosa.
Stability challenges: LGD-4033 needs to avoid hydrolysis (especially in aqueous solvents) and oxidation degradation in liquid formulations. Adding antioxidants (such as vitamin E) and storing in a dark place can extend the shelf life to 12-18 months.
Individual differences and metabolism
CYP3A4 polymorphism: LGD-4033 is mainly metabolized by the liver enzyme CYP3A4, generating an inactive metabolite. CYP3A4 gene polymorphism may lead to differences in metabolic rate, and dose optimization through therapeutic drug monitoring (TDM) is necessary.
First-pass effect: Although the oral bioavailability is as high as 90%, individual differences in liver metabolism capacity may still cause fluctuations in blood drug concentration (±20%).
Drug interactions
CYP3A4 inhibitors: When combined with strong CYP3A4 inhibitors such as ketoconazole and ritonavir, the blood concentration of LGD-4033 may increase by 2-3 times, increasing the risk of side effects.
CYP3A4 inducers: When combined with CYP3A4 inducers such as rifampicin and carmustine, the metabolism accelerates, potentially leading to a decrease in drug efficacy.
Clinical data and dose optimization
Dose-dependent absorption
Linear pharmacokinetics: In the 1-10 mg/day dose range, the blood drug concentration is proportional to the dose. Liquid formulations need to ensure dose accuracy through precise measurement (such as droppers or measuring cups) to avoid errors (±10%).
Typical dose regimen:
Muscle-building period: 4-12 mg daily, for 8-12 weeks, combined with a high-protein diet and resistance training.
Fat loss period: 2-5 mg daily, protecting lean body mass and avoiding muscle loss.
Elderly population: 1-2 mg daily, with monitoring of bone density and prostate-specific antigen (PSA).
Half-life and dosing interval
Elimination half-life: 24-36 hours, supporting once-daily administration. Liquid formulations need to ensure that the proportion of metabolites does not exceed the limit during storage (such as -20°C freezing).
Cycle management: Long-term use may lead to endogenous testosterone suppression (about 50% reduction), and it is recommended to limit the cycle to no more than 12 weeks, followed by 4 weeks of PCT (such as tamoxifen 20 mg/day).
Safety and risk control
Side effect monitoring
Short-term side effects: Headache (15%), dry mouth (10%), muscle spasms (8%), and mood swings (5%), most of which are mild and reversible.
Long-term risks:
Lipid metabolism disorder: HDL-C decreases by 40%, LDL-C increases by 30%, increasing cardiovascular risk. Hepatotoxicity: In some cases, reports indicate an increase in transaminase levels (ALT/AST > 3 times the upper limit), and regular monitoring of liver function is required.
Hormone suppression: Total testosterone decreases by 50%, and free testosterone decreases by 40%. It is necessary to restore through PCT.
Precautions and Contraindications
Contraindicated populations: Pregnant women, minors, patients with prostate cancer or breast cancer should avoid use.
Drug combination: Avoid using in combination with antiepileptic drugs (such as carbamazepine) or antiviral drugs (such as ritonavir) to prevent metabolic interactions.
Special risks of liquid formulations: Be vigilant for microbial contamination (non-sterile formulations) and long-term toxicity of solvent residues (such as ethanol).
Hot Tags: lgd-4033 liquid, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, 1 3 dimethylpentylamine hydrochloride, Iodomethane d3, Larocaine powder, Peptide, pure benzocaine powder, Xylazine hydrochloride